Skip to content
OpenCapital
Get started

Kyverna Therapeutics, Inc. KYTX Current Debt

Current Debt at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.31B-35.1%
Gilead Sciences logo
Gilead SciencesGILD
$1.31B-53.2%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$11K-91.3%

Other financials

Income statement

See full
Operating income-$41.4M+12.7%
Net income-$39.7M+11.0%
EPS (diluted)-$0.66+35.9%

Balance sheet

See full
Cash & equivalents$32.2M-43.4%
Total debt$9.2M+32.1%
Total equity$195.6M-12.7%
Total assets$257.0M-1.4%

Cash flow

See full
Operating cash flow-$41.6M+7.4%
CapEx$2.0K-98.0%
Free cash flow-$33.5M+10.8%

Valuation

See full
Market cap$498.52M+276%
Enterprise value$475.49M+475%

Returns & leverage

See full
Return on equity-74.5%+74.4pp
Debt / equity0×0.0×
Current ratio8.1×+0.7×

Where this comes from

Reported directly by Kyverna Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kyverna Therapeutics, Inc.'s current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kyverna Therapeutics, Inc.'s current debt?
Kyverna Therapeutics, Inc. (KYTX) reported current debt of $221K in Q1 2026.
How has Kyverna Therapeutics, Inc.'s current debt changed year-over-year?
Kyverna Therapeutics, Inc.'s current debt decreased by 56.4% year-over-year, from $507K to $221K.
What is the long-term trend for Kyverna Therapeutics, Inc.'s current debt?
Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s current debt has grown at a -43.3% compound annual growth rate (CAGR), from $956K to $307K.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.